Autopsy report · NCT01327521

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

“Accrual below target levels”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Albert Koong

Sponsor type

University, hospital or other

Conditions

Carcinoma, Hepatocellular

Interventions

CyberKnife; TACE; CT Contrast; doxorubicin; Epirubicin; 5-fluorouracil

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma
  “Low accrual; target accrual not met” (80% match in meaning)
• Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
  “Low Accrual” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.